Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02221778 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv9
  2. Primary and study completion dates: Aug 2024 to Dec 2024v8
  3. Primary completion date: Mar 2020 to Aug 2024 Completion date: Jul 2020 to Aug 2024v7 Show 1 more changeShow less
    • Completion date: Jul 2020 to Aug 2024
  4. Trial status: Recruiting to Active, Not Recruiting Primary completion date: Sep 2019 to Mar 2020 · Site details revisedv6 Show 2 more changesShow less
    • Primary completion date: Sep 2019 to Mar 2020
    • Site details revised
  5. Primary completion date: Nov 2018 to Sep 2019 Site contact updatedv5 Show 1 more changeShow less
    • Site contact updated
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Aug 2018 to Nov 2018 Site details revisedv4 Show 1 more changeShow less
    • Site details revised
  2. Phase: Not applicable to Phase 2 Enrollment target: 10 to 25 · Primary completion date: Aug 2015 to Aug 2018 · Completion date: Jul 2017 to Jul 2020v3 Show 3 more changesShow less
    • Enrollment target: 10 to 25
    • Primary completion date: Aug 2015 to Aug 2018
    • Completion date: Jul 2017 to Jul 2020
  3. Eligibility criteria revisedv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a pilot study where patients with Hepatocellular Carcinoma (HCC) that have failed Transarterial Chemoembolization (TACE) will be treated with Stereotactic Body Radiation Therapy (SBRT). The focus of the study will be to evaluate safety and efficacy in our population of patients.
Trial Details
NCT Number NCT02221778
Lead Sponsor University of Sao Paulo
Conditions Carcinoma, Hepatocellular
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov